Roth Capital Remains Bullish as Flex Pharma (FLKS) Completes NLC Enrollment

Roth Capital reiterated a Buy rating and $27.00 price target on Flex Pharma (NASDAQ: FLKS) following the company's completion of enrollment in the NLC study using its proprietary formulation. Two additional milestones in 1H16 are the expected ex-U.S. ALS and MS studies. Roth believes that time to data should be short as study duration and followup is short.

Analyst Joseph Pantginis commented, "With completion of enrollment in the NLC study using FLKS' proprietary formulation, we await data in 1Q16, which should inform the next NLC study with single-agent FLX-787. Two additional milestones in 1H16 are the expected ex-U.S. ALS and MS studies. We believe time to data should be short as study duration and followup is short given that investigators will assess effects on cramps and spasms. Reiterate Buy."

For an analyst ratings summary and ratings history on Flex Pharma click here. For more ratings news on Flex Pharma click here.

Shares of Flex Pharma closed at $12.07 yesterday.

You May Also Be Interested In

• Emkay Global Starts Urban Company (URBANCO:IN) at Buy (1)
• UBS Downgrades Klarna (KLAR) to Neutral
• Cummins (CMI) PT Lowered to $675 at Jefferies